Companies making modified TCRs as drug products for Cancer Immunotherapy have a current pressing need to identify off-target binding of their products to ensure safety; there have been several reported patient deaths in clinical trials due to cardiac or gastric inflammation as a direct result of treatment with modified TCRs.
Our project aims to investigate and validate a broad screening solution that would enable more comprehensive and reliable screening of products earlier in development. This could reduce the risk of medical side-effects or fatalities during clinical trials and speed up development and deployment of more effective cancer treatments.
Orbit Discovery was established in November 2015 as a spin-out from Oxford University. The founding IP relates to our peptide display platform and its use for the identification of novel peptides and for the identification of T-cell epitopes in high throughput screens. We collaborate with industry to identify and characterise advanced therapeutics for a range of diseases.
We are pleased to announce that Innovate UK, the UK’s innovation agency, has recognised this opportunity to improve Cancer Immunotherapy and awarded Orbit a grant to test the feasibility of this off-target screening with our peptide display platform over the next 18 months.